METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer
Lung cancer remains a leading cause of cancer-associated mortality worldwide, however, molecular mechanisms underlying lung cancer tumorigenesis and progression remain unknown. Here, we report evidence showing that one member of the mammalian methyltransferase-like family (METTL), METTL7B, is a pote...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.00178/full |
| id |
doaj-5e044c708762482fafa302eaaab71631 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Dongcheng Liu Dongcheng Liu Wei Li Wei Li Fuhua Zhong Jianhua Yin Wei Zhou Shixuan Li Xuefeng Sun Jing Xu Guofeng Li Yuxin Wen Jiaqing Wang Malin Hong Zhiqiang Cheng Zhiqiang Cheng Jimin Yuan Lingyun Dai Jichao Sun Jigang Wang Chen Qiu Guangsuo Wang Chang Zou Chang Zou |
| spellingShingle |
Dongcheng Liu Dongcheng Liu Wei Li Wei Li Fuhua Zhong Jianhua Yin Wei Zhou Shixuan Li Xuefeng Sun Jing Xu Guofeng Li Yuxin Wen Jiaqing Wang Malin Hong Zhiqiang Cheng Zhiqiang Cheng Jimin Yuan Lingyun Dai Jichao Sun Jigang Wang Chen Qiu Guangsuo Wang Chang Zou Chang Zou METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer Frontiers in Pharmacology METTL7B non-small cell lung cancer proliferation tumorigenesis cell cycle |
| author_facet |
Dongcheng Liu Dongcheng Liu Wei Li Wei Li Fuhua Zhong Jianhua Yin Wei Zhou Shixuan Li Xuefeng Sun Jing Xu Guofeng Li Yuxin Wen Jiaqing Wang Malin Hong Zhiqiang Cheng Zhiqiang Cheng Jimin Yuan Lingyun Dai Jichao Sun Jigang Wang Chen Qiu Guangsuo Wang Chang Zou Chang Zou |
| author_sort |
Dongcheng Liu |
| title |
METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer |
| title_short |
METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer |
| title_full |
METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer |
| title_fullStr |
METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer |
| title_full_unstemmed |
METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer |
| title_sort |
mettl7b is required for cancer cell proliferation and tumorigenesis in non-small cell lung cancer |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Pharmacology |
| issn |
1663-9812 |
| publishDate |
2020-02-01 |
| description |
Lung cancer remains a leading cause of cancer-associated mortality worldwide, however, molecular mechanisms underlying lung cancer tumorigenesis and progression remain unknown. Here, we report evidence showing that one member of the mammalian methyltransferase-like family (METTL), METTL7B, is a potential molecular target for treatment of non-small cell lung cancer (NSCLC). METTL7B expression was elevated in the majority of NSCLC comparing to normal tissues. Increased expression of METTL7B contributed to advanced stages of tumor development and poor survival in NSCLC patients. Lentivirus-mediated shRNA silencing of METTL7B suppressed proliferation and tumorigenesis of cancer cells in vitro and in vivo. Investigation on gene expression profiles of NSCLC cells revealed that abundant cell cycle related genes were downregulated in the absence of METTL7B. Pathway enrichment analysis indicated that METTL7B participated in cell cycle regulation. Notably, CCND1, a key regulator for G1/S transition, was significantly decreased with the depletion of METTL7B, resulting in G0/G1 arrest, indicating that METTL7B is critical for cell cycle progression. Taken together, our findings implicate that METTL7B is essential for NSCLC development and progression. METTL7B might serve as a potential therapeutic target for NSCLC. |
| topic |
METTL7B non-small cell lung cancer proliferation tumorigenesis cell cycle |
| url |
https://www.frontiersin.org/article/10.3389/fphar.2020.00178/full |
| work_keys_str_mv |
AT dongchengliu mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT dongchengliu mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT weili mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT weili mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT fuhuazhong mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT jianhuayin mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT weizhou mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT shixuanli mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT xuefengsun mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT jingxu mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT guofengli mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT yuxinwen mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT jiaqingwang mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT malinhong mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT zhiqiangcheng mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT zhiqiangcheng mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT jiminyuan mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT lingyundai mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT jichaosun mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT jigangwang mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT chenqiu mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT guangsuowang mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT changzou mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer AT changzou mettl7bisrequiredforcancercellproliferationandtumorigenesisinnonsmallcelllungcancer |
| _version_ |
1724664118142566400 |
| spelling |
doaj-5e044c708762482fafa302eaaab716312020-11-25T03:08:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-02-011110.3389/fphar.2020.00178518090METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung CancerDongcheng Liu0Dongcheng Liu1Wei Li2Wei Li3Fuhua Zhong4Jianhua Yin5Wei Zhou6Shixuan Li7Xuefeng Sun8Jing Xu9Guofeng Li10Yuxin Wen11Jiaqing Wang12Malin Hong13Zhiqiang Cheng14Zhiqiang Cheng15Jimin Yuan16Lingyun Dai17Jichao Sun18Jigang Wang19Chen Qiu20Guangsuo Wang21Chang Zou22Chang Zou23Department of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaIntegrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, ChinaDepartment of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaShenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Thoracic Surgery, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Thoracic Surgery, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Pathology, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Thoracic Surgery, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Thoracic Surgery, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Thoracic Surgery, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaShenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Pathology, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaThe Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaThe Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaThe Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaThe Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Respiratory and Critical Medicine, Shenzhen People's Hospital, Second Clinical Medical College, Jinan University, Shenzhen, ChinaDepartment of Thoracic Surgery, the First Affiliated Hospital of Southern University of Sciences and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaDepartment of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, the First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen, ChinaShenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, ChinaLung cancer remains a leading cause of cancer-associated mortality worldwide, however, molecular mechanisms underlying lung cancer tumorigenesis and progression remain unknown. Here, we report evidence showing that one member of the mammalian methyltransferase-like family (METTL), METTL7B, is a potential molecular target for treatment of non-small cell lung cancer (NSCLC). METTL7B expression was elevated in the majority of NSCLC comparing to normal tissues. Increased expression of METTL7B contributed to advanced stages of tumor development and poor survival in NSCLC patients. Lentivirus-mediated shRNA silencing of METTL7B suppressed proliferation and tumorigenesis of cancer cells in vitro and in vivo. Investigation on gene expression profiles of NSCLC cells revealed that abundant cell cycle related genes were downregulated in the absence of METTL7B. Pathway enrichment analysis indicated that METTL7B participated in cell cycle regulation. Notably, CCND1, a key regulator for G1/S transition, was significantly decreased with the depletion of METTL7B, resulting in G0/G1 arrest, indicating that METTL7B is critical for cell cycle progression. Taken together, our findings implicate that METTL7B is essential for NSCLC development and progression. METTL7B might serve as a potential therapeutic target for NSCLC.https://www.frontiersin.org/article/10.3389/fphar.2020.00178/fullMETTL7Bnon-small cell lung cancerproliferationtumorigenesiscell cycle |